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Abstract
This commentary describes how the Brazilian Ministry of Health’s (MoH) research support policy fulfilled the
National Agenda of Priorities in Health Research (NAPHR). In 2003, the MoH started a democratic process in order
to establish a priority agenda in health research involving investigators, health managers and community leaders.
The Agenda was launched in 2004 and is guiding budget allocations in an attempt to reduce the gap between
scientific knowledge and health practice and activities, aiming to contribute to improving Brazilian quality of life.
Many strategies were developed, for instance: Cooperation Agreements between the Ministry of Health and the
Ministry of Science and Technology; the decentralization of research support at state levels with the participation
of local Health Secretariats and Science and Technology Institutions; Health Technology Assessment; innovation in
neglected diseases; research networks and multicenter studies in adult, women’s and children’s health;
cardiovascular risk in adolescents; clinical research and stem cell therapy. The budget allocated by the Ministry of
Health and partners was expressive: US$419 million to support almost 3,600 projects. The three sub-agenda with
the higher proportion of resources were “industrial health complex”, “clinical research” and “communicable
diseases”, which are considered strategic for innovation and national development. The Southeast region
conducted 40.5% of all projects and detained 59.7% of the resources, attributable to the concentration of the most
traditional health research institutes and universities in the states of São Paulo and Rio de Janeiro. The second
most granted region was the Northeast, which reflects the result of a governmental policy to integrate and
modernize this densely populated area and the poorest region in the country. Although Brazil began the design
and implementation of the NAPHR in 2003, it has done so in accordance with the ‘good practice principles’
recently published: inclusive process, information gathering, careful planning and funding policy, transparency and
internal evaluation (an external independent evaluation is underway). The effort in guiding the health research
policy has achieved and legitimated an unprecedented developmental spurt to support strategic health research.
We believe this experience is valuable and applicable to other countries, but different settings and local political
circumstances will determine the best course of action to follow.
Background
T h ee s t a b l i s h m e n to far e s e a r c hp r i o r i t ya g e n d ai s
important to ensure the best possible use of available
r e s o u r c e s ,t oi d e n t i f yt h en ecessary resources against
competing demands and to strengthen ties between pol-
icy, health practice, scientific knowledge and technologi-
cal development [1]. The Global Forum for Health
Research coined the term “10/90 gap” to capture the
major imbalance in the allocation of health research
funds, indicating that the magnitude of health problems
is not proportional to the resources invested in addres-
sing those [2].
The traditional mode of science production was based
on universities and research institutes, with agenda set
by investigators, where research was dichotomized as
basic or applied, with a disciplinary approach. This is
gradually replaced by a participatory mode; the new sys-
tem is characterized by research networks, agenda
* Correspondence: leopac@unb.br
1Departamento de Saúde Coletiva, Universidade de Brasília. Campus
Universitário Darcy Ribeiro, CEP 70910-900, Brasília, DF, Brazil
Full list of author information is available at the end of the article
Pacheco Santos et al. Health Research Policy and Systems 2011, 9:35
http://www.health-policy-systems.com/content/9/1/35
© 2011 Pacheco Santos et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.defined in an application context, research aimed at pro-
blem-solving, transdisciplinary focus, assessment of aca-
demic merit and social relevance [3].
In this context, the formulation of a national agenda
for health research must consider the population’s level
of development, demographic and epidemiologic profile,
current level of knowledge and shortcomings, together
with the diversity of regional situations, participation of
public, philanthropic and private institutions, as well as
intellectual property policies [4].
Research in Brazil gained magnitude, a fact acknowl-
edged by the international press ("An emerging power
in research; science in Brazil”. The Economist,J a n u a r y
6th, 2011 <http://www.economist.com/node/17851421
> ) .H o w e v e r ,u pu n t i lr e c e n t ly, there was an incipient
articulation between the Unified Public Health System
(SUS) and the National Science and Technology System,
which did not guarantee the application of results and
findings to meet the SUS’s social needs and purposes.
To reverse this situation it was essential to bring the
Ministry of Health to the center of research decisions,
enabling integration between those who investigate,
request, implement and use health knowledge.
The Department of Science and Technology (DECIT)
at the Brazilian Ministry of Health (MoH) is responsible
for promoting research to improve the health system. Its
primary challenge is to guarantee scientific and techno-
logical development as an important and permanent
tool for guiding the country to an evidence-based SUS
that promotes universality, integrity and equity.
An essential step was establishing a National Agenda
of Priorities in Health Research (NAPHR). The process
started in 2003 when a Technical Advisory Committee
composed of 20 distinguished scientists and policy-
makers was appointed. Shortly thereafter, a Seminar was
organized with 510 professionals, among which health
researchers (68%) and healthcare policymakers or provi-
ders (32%), who participated in the elaboration of the
first NAPHR draft. The final choice regarding partici-
pants guaranteed a fair distribution as far as sex and
place of origin, so that the country’s five regions and
most of the 27 states were represented [5]. The draft
Agenda was submitted to public consultation on the
website for 45 days when 1,900 individuals registered
online; 360 comments and contributions were received
and analyzed. The next step was very important to legit-
imate the process: the NAPHR was presented, discussed
and approved during the National Conference [5] as
described below.
In 2004 the Brazilian Ministry of Health fostered the
organization of the 2nd National Conference on Science,
Technology and Innovation (STI) in Health. As usual in
National Health Conferences, a tradition in the SUS, the
process was democratic with inputs from investigators,
stakeholders and the public in general. It involved
15,000 participants in 307 local conferences, which indi-
cated part of the 644 delegates for the National Confer-
ence. The delegates discussed and approved the
National Policy on STI in Health and the NAPHR. The
Policy is guided by six principles: (a) improving the Bra-
zilian population’s health conditions in the short, med-
ium and long run; (b) overcoming all forms of inequity
and discrimination (regional, social, ethnical, gender and
others); (c) respect to people’s lives and dignity; (d)
ensuring implementation of high ethical standards in
health research; (e) respect to methodological and philo-
sophical plurality; (f) social inclusion, citizen control and
respect to the environment and sustainability [6]. The
Conference was a challenge for scientists, health provi-
ders and community leaders. They had never before
interacted in such depth to openly discuss their points
of view, not always an easy task, as pointed out by some
authors [7].
Since then, research supported by DECIT has been
guided by the NAPHR, which is organized into 24 sub-
agenda according to life cycle, race, disease or damage and
other criteria. The complete list of sub-agendas is available
on the web site at the following address: <http://bvsms.
saude.gov.br/bvs/publicacoes/agenda_ingles.pdf >[8].
Equally important to setting a National Priority Agenda is
how it is implemented. This commentary intends to ana-
lyze how the Brazilian Ministry of Health research support
policy fulfilled the 2004 NAPHR. Recently, there has been
a greater recognition of the value of reviewing the research
performed and/or the funding allocated based on pre-
viously established priorities [9].
Institutional partnerships to implement the National
Agenda of Priorities
An important step towards the rapid implementation of
the NAPHR was the signing of Cooperation Agreements
between the Ministry of Health (MoH) and the Ministry
of Science and Technology (MST), from 2004 to 2012.
This partnership involved the Financier of Studies and
Projects (Financiadora de Estudos e Projetos, FINEP)
and the National Council of Scientific Development
(Conselho Nacional de Desenvolvimento Científico e
Tecnológico, CNPq), both belonging to the MST. The
agreements allow for a budgetary expansion to fund
research and innovation projects, co-financed with the
MST Health Sector Fund. State Foundations for
Research Support (FAP) are also important MoH part-
ners in the effort to implement the NAPHR, as we will
explain in more detail in the following sections.
Decentralization and democratization of health research
The infrastructure regarding research facilities, trained
investigators, postgraduate courses and, consequently,
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Southeast, the richest and most developed region. In the
nineties, this region used to attract the best scientists
from all over the country in their search for better
working conditions. This region received 48% of the
1,359 scientists who migrated internally from 1993 to
1999, when there was also an appreciable brain drain
out of the country (n = 959) [10].
The MoH decided to foster health research in a
decentralized way and initiated the project known as
Research for SUS Program (PPSUS). In 2002/3 there
were 147 research projects funded by this decentralized
mechanism, resulting from public calls for proposals ran
in 10 states. Considering the need to be more inclusive,
the program was extended to all 26 Brazilian states,
besides the Federal District, and in the next year, 2004,
financed almost 400 projects. Since then, there are regu-
lar calls for proposals about every two years. The MoH,
through DECIT, is the national coordinator of PPSUS
and FAPs act as co-financiers and executing agents. The
local FAPs and the state health departments are
involved in all stages, from the selection of priorities to
the judgment of proposals and the evaluation of final
results.
The main objective of this initiative is to reduce regio-
nal inequities in scientific knowledge production. The
accomplishment of this policy may be ascertained by the
increased participation of state investments in health
science and technology at each edition of the program.
The largest number of PPSUS projects was approved
in the Northeast region (Table 1). However, the greatest
sum of investment was allocated to the Southeast. This
fact is related to some large vaccine development pro-
jects financed in the later, with large investments from
the local FAPs.
One indicator of PPSUS’s success is scientific publica-
tions and qualification of human resources: 668 Masters
Dissertations and 332 Doctoral Theses received support
from the program and 25 patents were registered. The
Northeast region reported the largest number of aca-
demic degrees, 322 Master and Doctoral degrees (corre-
sponding to 32%), ahead of the most developed and
populated Southeast region. This is an accomplishment
of PPSUS in the direction of decreasing regional
disparities.
Health Technology Assessment for SUS
New drugs, equipments, medical devices and procedures
are constantly being developed. Ever since 2003, DECIT
coordinates the MoH Permanent Working Group on
Health Technology Assessment (HTA). In 2005, the
MoH appointed a commission to elaborate the National
Policy on Health Technology Management (PNGTS),
which was approved in 2009 after four years of intense
work, reaching a consensus among the representatives
of various sectors: health, legal, civil society. The
National Commission for Health Technology Incorpora-
tion (CITEC) was created in 2006.
In 2004 DECIT started the HTA calls for proposals,
totaling 207 projects financed with an investment of
around U$10.5 million (U$1.00 = R$1.688 on January
2011). The aim is to impel the SUS towards the regular
use of scientific evidence in the decision-making
process.
In 2006, DECIT assigned a team specifically dedicated
to HTA to subsidize decisions made by the Minister of
Health regarding the incorporation of technologies. At
this time, the department joined the International Net-
work of Agencies for Health Technology Assessment-
INAHTA, a society which brings together 45 agencies
from 22 countries. This initiative enabled a greater
exchange of information and experiences in the global
context. As a result of this effort, Rio de Janeiro, Brazil,
was the venue for the 2011 HTAi International Meeting.
Between 2004 and 2010 the Brazilian Cochrane Colla-
boration was contracted by DECIT to perform 66 sys-
tematic reviews; 54 were concluded and most of them
were used by decision makers. For instance, the
Table 1 Proportion of projects approved and amount of resources allocated by the Ministry of Health and partners in
the decentralized PPSUS program and academic degrees related to the projects, according to the geographic region,
Brazil, 2004-2009
Region Number of PPSUS
projects
Amount invested in
PPSUS
(U$ millions)
Proportion of Master + Doctor
degrees (%)
Proportion of the Brazilian
population (%)
Midwest 152 3.9 8.1 7.3
Northeast 581 14.3 32.1 28.0
North 236 9.8 7.6 8.0
Southeast 459 36.8 28.9 42.3
South 347 10.3 23.3 14.4
Total 1,775 75.1 100.0 100.0
Source: data summaries were calculated by the authors based on information taken from: http://www.saude.gov.br/sisct, and http://www.saude.gov.br/
pesquisasaude, captured on Jan 21, 2011.
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was to support decision making processes: (a) twenty-
four were sent to two high level decision units: the
National Commission for Health Technologies Incor-
poration-CITEC and the ministerial group elaborating
the Clinical Guidelines; the reviews were incorporated
to the body of evidence used by these two units in their
decision making process; (b) seven reviews were used
straight away to support CITEC decisions. Another
seven were employed to compose DECIT’s Health Tech-
nology Assessment Report.
In 2008, the Brazilian Network for Technology Assess-
ment in Health-REBRATS was established, with the spe-
cific goal of supporting the development of priority
studies in HTA, to disseminate the studies produced
and to establish guidelines for the development and
standardization of HTA methods. Presently, there are 44
member institutions in the REBRATS. The network’s
portal publishes, in Portuguese, over 200 academic stu-
dies, systematic reviews and economic evaluations and
accepts proposals for new studies (available at: http://
www.saude.gov.br/rebrats).
Research and innovation in neglected diseases-
overcoming the 10/90 gap
This is also another strategic research policy. From 2004
to 2009, DECIT and its partners invested around US
$70.8 million and launched several calls for proposals,
specific for these diseases. The fruitful partnership with
the MST and FAPs resulted in an unprecedented pool
of financial resources to investigate malaria and dengue
fever, via joint calls for proposals in 2009. The first was
the Malaria Research Network, with the financial parti-
cipation of seven states, besides the Federal agencies,
investing US$7.5 million. For the Dengue Fever
Research Network, co-financing involved 20 states, with
US$5.2 million provided by DECIT and partners.
Treatment for most neglected diseases remains an
unsolved problem. Recently, a project supported by
DECIT showed promising results in the treatment of
the cutaneous manifestations of Leishmania braziliensis.
The randomized controlled trial indicated that after six
months of treatment, the oral drug was more effective
when compared to the traditional antimony injections
regarding clinical remission and treatment compliance,
although with a similar incidence of side effects [11].
Research networks and multicenter studies
In order to optimize resources and results, research net-
works and multicenter studies are encouraged. The lar-
gest cohort of adults in Latin America is the
Longitudinal Study of Adult Health, ELSA Brazil, which
investigates the determinants, incidence and time course
of diabetes and cardiovascular disease in a sample of 15
thousand adults aged between 35 and 74 years old.
There are six research centers involved, located in three
Brazilian regions: Southeast, South and Northeast. The
Ministry of Health and the Ministry of Science and
Technology invested US$13.4 million in 2006. More
recently, in 2009-2010, DECIT granted around US$4
million to ensure the study’s continuity and the prepara-
tions for the second wave of data collection. On Decem-
ber 3, 2010, ELSA Brazil reached 102% of the set target,
with 15,050 individuals enrolled at baseline to be fol-
lowed in the subsequent phases.
The National Demography and Health Survey of
Women and Children (DHS 2006/7), which aimed to
update the health indicators of women and children and
its differentials and determinants, was planned and
financed by DECIT. The study received an investment
of US$4.6 million that was shared with the Coordination
of Food and Nutrition at the MoH.
The Study of Cardiovascular Risk in Adolescents
(ERICA) began fieldwork in 2010 and aims to estimate
the prevalence of diabetes mellitus, obesity, cardiovascu-
lar risk factors, inflammatory markers and insulin resis-
tance in 74,000 adolescents 12 to 17 years of age in
Brazilian cities with more than 100,000 inhabitants. The
study is integrated by 27 research institutions represent-
ing all regions of Brazil. In 2008, the MoH and the MST
invested US$3.8 million, and in 2010 DECIT provided
an additional US$1.2 million to ensure the completion
of all laboratory tests.
Clinical research directed towards SUS needs
Supporting Clinical Research Centers in teaching hospi-
tals in order to answer questions relevant to the SUS
was considered essential. Therefore, a joint venture of
the MoH and the MST invested US$20.8 million in the
National Clinical Research Network (RNPC), launched
in 2005. The 19 centers that presented the required cri-
teria, located in all Brazilian regions, were granted funds
over a two-year period to refurbish or build research
facilities, to acquire equipment and to hire specialized
personnel.
Between 2006 and 2008, DECIT and partners invested
US$20 million in three calls for proposals to finance
RNPC centers to develop studies in areas such as: (1)
recombinant human insulin analogue, (2) treatment of
leishmaniasis, (3) bariatric surgeries in the SUS, (4)
obstructive sleep apnea, (5) osteoporosis, (6) leprosy
neuropathy and (7) treatments for prevention of cardio-
vascular events in hypertensive patients and patients
with resistant hypertension.
In 2009, the RNPC was expanded: 13 new centers met
the criteria and were eligible to join the network. This
allowed for adjusting the role of clinical research to the
strategic route of scientific development, accompanying
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complex.
In 2010, DECIT and CNPq financed projects to con-
duct phase II or III clinical trials in partnership with pri-
vate or state-owned companies in order to develop
strategic products for the SUS. Three projects were
approved: a national ventricular assist device (VAD);
skin wound healing action of the proteolytic fraction of
a plant extract, and the treatment of venous ulcers with
fibrin sealant derived from venoms. The current chal-
lenges are related to sustainability in financing and
managing the Clinical Research Centers.
National Network of Cell Therapy-innovation for the
future
The seminal project in cell therapy started in 2004:
DECIT and partners granted US$7.9 million for
“MiHeart”, one of the world’s largest stem cell clinical
trials for cardiopathies [12]. The study organized four
branches, dedicated to Chagas heart disease, dilated car-
diomyopathy, ischemic heart disease and acute myocar-
dial infarction. More than 30 research centers across the
country participate in this study.
In 2005, the Brazilian Congress approved the Bio-
safety Act, number 11105/2005, giving breadth to scien-
tific development in the promising area of stem cell
therapy and regenerative medicine. There were three
calls for proposals, from 2005 to 2008. Eight Cell Tech-
nology Centers (CTCs) were supported to produce var-
ious types of human stem cells in conditions of good
manufacturing practices, being pluripotent stem cells
(embryonic and iPSC) or the multipotent (adult hemato-
poietic, mesenchymal, neural and cardiac). These initia-
tives led to the constitution of the National Network of
Cell Therapy (RNTC) consisting of 52 research groups
and eight CTCs. The total investment of DECIT, Finep
and the National Bank of Social and Economic Develop-
ment (BNDES) in this area reached US$49 million. The
primary targets are heart disease, chronic degenerative
disease, trauma and diseases associated with aging.
Some important results are emerging. A research pro-
ject funded by DECIT and CNPq in 2005 allowed for
the development of a fully national line of embryonic
stem cells in São Paulo. Another important result
obtained by the same group in Rio de Janeiro, was the
development of the first Brazilian strain of induced plur-
ipotent stem cells (iPSC). The Brazilian effort in this
novel area of stem cell research was recently classified
as innovative by an independent study [13].
Meeting unexpected challenges: the Influenza A
pandemic
In 2009, Brazil was hit by influenza A and the MoH
pleaded with the Ministry of Planning for a US$3
million supplementary budget in order to invest in stra-
tegic research to face the H1N1 pandemic. DECIT
financed several projects in close partnership with the
Health Surveillance Secretariat, ranging from the epide-
miology of risk factors for disease severity and death, to
monitoring genetic mutations of the Influenza A virus
circulating in Brazil. Some investments were made in
essential innovations for the surveillance of influenza A.
Most of the projects have already presented results.
Initially, Brazil, as well as most countries, was totally
dependent on inputs and reagents obtained from the US
Center for Disease Control for the diagnostic inputs.
The “Nationalization of biotechnological products for
the molecular diagnosis of Influenza A (H1N1)” project
was financed by DECIT in 2009 and six months later
the investigators launched the National Diagnostic Kit,
promoting access to inputs from molecular biology to
a c h i e v ed i a g n o s t i ct e s t sf o r the Influenza A pandemic
virus. Moreover, biotechnological platforms have been
deployed in three key national reference laboratories for
influenza and in three public health laboratories; equip-
ment maintenance and human resources technical train-
ing was also guaranteed ("Pesquisadores brasileiros
criam exame molecular que reduz de oito para quatro
horas o diagnóstico da gripe A”. Correio Brazilense June
21, 2010 <http://www.correiobraziliense.com.br/app/
noticia/ciencia-e-saude/2010/06/26/interna_ciencia_-
saude,199542/index.shtml >)
Obstacles in the implementation process
To reach the results presented here, many barriers were
encountered and partially overcome. The financing
mechanisms available at the MoH are not adequate to
sponsor research projects and the bureaucracy involved
hinders the flow of resources from the federal level to
the principal investigators and research institutes. The
option to operate the MoH funds through other federal
MST agencies, like FINEP and CNPq, on one hand con-
tributed to speed the organization, judgment and disbur-
sement of funds for the Calls for Proposals, but on the
other increased the chance that scientists simply forget
the origin of the resources (MoH) and acknowledge
them as being MST funds.
Inducement mechanisms were not always successful.
Sometimes topics of special interest to the MOH were
included in Calls for Proposals, but high quality projects
were not submitted. Possible explanations to these facts
are failures in the research capacity and/or a mismatch
between Ministerial priorities and the investigators’
research interests. However the events were rare, and
did not affect the research agenda fulfillment.
The potential conflicts of interest in the peer review
process during the judgment of calls for proposal were
overcome by different mechanisms. In the decentralized
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tists rather close to each other. In most cases there was
a “crossover” mechanism and scientists from other states
were summoned to analyze the research proposals. In
the national bids CNPq and FINEP have traditional
mechanisms to override conflicts of interest. In a few
cases scientists working abroad were invited to judge
projects.
Evaluation of the Agenda’s fulfillment
The methodology used to assess the NAPHR fulfillment
was to compare the investments in research projects
with the stated priorities. The analysis was based on
data from two DECIT information systems: Pesquisa-
Saude and SisCT (available at: <http://www.saude.gov.
br/pesquisasaude > and <http://www.saude.gov.br/sisct
>).
The first system was devised to provide transparency
and accountability to DECIT processes. It contains the
following information about each project: type of call
for proposals; title of the project; abstract; keywords;
sub-agenda; type and nature of the research; sector of
application; the principal investigator (name, contact,
affiliation); year; types of support; partnerships and
resources approved. The classification of sub-agenda is
done by the principal investigator or by DECIT staff.
The SisCT database was built for internal use, to aid
the judgment process of grant awards. Once projects are
approved and contracts are signed, the SisCT software
feeds automatically the “PesquisaSaude” system. The
systems are updated daily; the information presented in
this commentary was downloaded on January 21, 2011.
Table 2 shows the global investment of DECIT and
partners in fostering research and innovation for health
between 2004 and 2009. The data is presented by type
of call for proposals (state calls, PPSUS, or national pub-
lic calls) and mode of selection (direct contracts), in
which bidding is not required.
In the period analyzed, there were 135 public calls for
proposals, financing 3,480 projects in addition to 106
projects contracted directly with investments of nearly
US$420 million. As shown, direct contracting is the
least common mode of action and represents about 3%
of financed projects and 11% of the resources invested.
DECIT disbursed approximately 60% of the total
amount. The remaining 40% came from different part-
ners, such as the Ministry of Science and Technology,
through the CNPq and FINEP (30% of resources); FAPs
with a 6% contribution and other sectors of the Ministry
of Health with 4% of the total.
We compared the priorities identified by the 24
NAPHR sub-agendas with the number of projects and
the amount invested in each one. The proportions sup-
ported were in line with the stated priorities as shown
below. Three major criteria guided funding: epidemio-
logic relevance in the Brazilian context, the needs of
the national public health system (SUS) and the devel-
opment of strategic areas in the national scientific sce-
nario. From 2004 to 2009, DECIT and partners
destined US$419 million to support more than 3,500
projects in accordance with the National Agenda, as
shown in Table 3. All sub-agenda were funded in dif-
ferent types of calls for proposals with an average
investment per project of US$117 thousand. The three
sub-agenda receiving the higher amount of resources
were “Industrial health complex” (26%), followed by
“Clinical research” (18%) and “Communicable diseases”
(16%). This reflects the priority given to these areas,
considered strategic for innovation and national devel-
opment; another factor is the need for heavy invest-
ments in equipment, laboratories and production
plants.
The sub-agenda “Bioethics and ethics in research”
received the lowest amount of funds and also the lowest
funds per project ratio, with an average of US$14 thou-
sand. DECIT initially financed small grants to empower
local Ethics Committees of the Research Institutes and
Universities, in order to improve quality and promptness
in the ethical evaluation of projects according to the
National Agenda.
Table 2 Projects financed and amount invested by the Ministry of Health and partners according to type of call for
proposals or mode of selection, Brazil, 2004-2009
Description Type of call for proposals or mode of selection
Decentralized calls
(PPSUS)
National calls for
proposals
Direct contract of strategic
projects
TOTAL
Number of calls for proposals (n) 77 58 77 212
Number of projects financed (n) 1,775 1,705 106 3,586
Resource invested (U$) 75 million 297 million 47 million 419 million
Resource/project invested (U$) 42 thousand 174 thousand 443 thousand 117 thousand
Source: data summaries were calculated by the authors based on information taken from: http://www.saude.gov.br/sisct and http://www.saude.gov.br/
pesquisasaude, captured on Jan 21, 2011.
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the figures reinforce that the priorities in health research
established by the National Agenda were observed. The
sub-agenda with the greatest number of studies
approved was, by far, “Communicable diseases”.F r o m
the total number of projects approved in this sub-
agenda, 60.6% (536 studies) were related to neglected
diseases. Among the seven neglected diseases elected by
the Brazilian government in 2008, dengue fever received
the highest amount of resources (19.9%), followed by
malaria (17.2%), leishmaniasis (16.1%), tuberculosis
(15.2%), leprosy (14.4%), Chagas disease (7.6%), and,
lastly, schistosomiasis (5.0%).
The proportion of resources and projects follows the
population distribution in all geographic regions (Figure
1). The Southeast region conducted 40.5% of all projects
and detained most of the resources (59.7%). Not surpris-
ingly, the most traditional health research institutes and
universities are located in the states of São Paulo and
Rio de Janeiro (Southeast region). The Northeast was
the second most financed region (both in number of
projects and amount of funds) and reflects the result of
a governmental policy to integrate and modernize this
densely populated area, which used to be the poorest
region in the country.
Figure 2 shows the three sub-agenda that received the
greatest amount of funds according to geographic
region. There are clear differences that reflect the stage
of regional development. In the Southeast, South and
Midwest, the most industrialized and developed regions,
there was a predominance of funds invested for research
in the “Industrial health complex” agenda. On the other
hand, in the Northern Amazonian region and in the
Northeast, most of the resources were allocated to
“Communicable diseases”, especially in the North. This
Table 3 Projects financed and the amount invested by
the Ministry of Health according to the sub-agenda,
Brazil, 2004-2009
Sub-agenda Number
of
projects
Amount
U$
(×1000)
Afro-Brazilian health 35 1,890
Bioethics and ethics in research 98 1,421
Child and adolescent health 124 5,368
Clinical research 233 74,840
Communicable diseases 672 66,534
Communication and information in health 59 2,981
Demography and health 3 5,605
Elderly health 64 5,347
Epidemiology 67 15,925
Food and nutrition 237 7,315
Health of individuals with disabilities 36 1,597
Health promotion 46 2,174
Health systems and policies 187 7,971
Health technology assessment/economic
evaluation
261 18,137
Health, environment, labor and bio-safety 86 6,409
Indigenous health 61 2,030
Industrial health complex 138 108,084
Mental health 153 8,498
Non communicable diseases 379 42,319
Oral health 125 3,331
Pharmaceutical care 163 12,281
Violence, accidents and trauma 98 3,641
Women health 163 9,701
Work and education management in health 98 5,485
Total 3,586 418,883
Source: data summaries were calculated by the authors based on information
taken from: http://www.saude.gov.br/sisct, and http://www.saude.gov.br/
pesquisasaude, captured on Jan 21, 2011.
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Figure 1 Proportion of projects approved and amount of
resources allocated by the Ministry of Health and partners
according to the geographic region. Brazil, 2004-2009. Source:
data summaries were calculated by the authors based on
information taken from: http://www.saude.gov.br/sisct and http://
www.saude.gov.br/pesquisasaude, captured on Jan 21, 2011.
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Figure 2 Proportion of investments by the Ministry of Health
and partners in the three most granted sub-agenda, according
to geographic region. Brazil, 2004-2009. Source: data summaries
were calculated by the authors based on information taken from:
http://www.saude.gov.br/sisct and http://www.saude.gov.br/
pesquisasaude, captured on Jan 21, 2011.
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innovative projects lead the agenda mainly in the South-
east, South and Midwest regions. On the other hand,
the epidemiologic profile regarding neglected diseases is
reflected in the poorest North and Northeast regions,
which, alongside the Midwest region, maintain some
excellent institutions and university hospitals that have a
large tradition in research on neglected diseases.
Discussion
Although Brazil began the design and implementation of
the National Agenda of Priorities in Health Research in
2003 it has done so in accordance with the ‘good prac-
tice’ principles recently published [9]. During the pre-
paratory work we considered the contextual factors and
the SUS principles; a comprehensive approach was
developed and employed; the process was inclusive and
geared towards balanced sex and regional participation
[5]; information gathering was extensive and resulted in
the publication of a book, with contributions from 22
leading scientists [14]; careful planning for implementa-
tion occurred, as evidenced by the funding allocation
policy, transforming priorities into actual research [5].
Deciding on priorities was achieved by the method of
consensus during the NAPHR Seminar in 2003 and the
National Conference of STI in Health in 2004 [5].
Immediately after the priorities were set, the imple-
mentation process started [5] facilitated by the political
decision to increase by almost five fold the DECIT bud-
get for the period 2004-2007 (for the subsequent bud-
getary period: PPA 2005-2011, the allocation was further
augmented by about 10%). As far as evaluation,a n
internal evaluation is presented here and an external
independent evaluation was contracted by DECIT in
2010 and is underway; final results are due in 2012.
Health research needs are dynamic and demand new
issues to be investigated, implying the need for a peri-
odic revision of the National Agenda. In 2010 the MoH
began to update the NAPHR which was widely dis-
cussed by investigators, health policymakers and civil
society. Preliminary results were presented to the
NAPHR Consultative Group Meeting in December
2010, aiming to construct a revised version in 2011/2.
The priority setting process was transparent from the
start, involving a large number of stakeholders, employ-
ing public consultation and afterwards the democratic
process of municipal, state and national conferences, the
usual way the SUS proceeds. All documents are freely
available on the web.
The Peruvian MoH’s research portfolio was recently
reported [15]; during the period 2004-2008 the budget
was U$ 5 million and 182 research projects were
approved and funded. Out of the presented research
projects, 45% were financed through a competitive fund,
40% were institutional, 9% came from regional/provin-
cial health directions and 5% were collaborative. Com-
pared to the Brazilian MoH experience, presented here,
we had a much higher proportion of projects funded by
competitive bids (97% of the projects and 89% of the
resources invested). The mean amount assigned to each
research project in Peru was U$ 33 thousand, whereas
in Brazil the average amount invested per project was of
U$ 117 thousand. Budget allocation according to study
subject was 61% for communicable diseases, 27% for
technological development and 12% for non-communic-
able diseases in Peru. In Brazil the three research sub-
jects receiving more funds were industrial health
complex (26%), clinical research (18%) and communic-
able diseases (16%).
The priority-setting criteria of NIH funding was ques-
tioned in the past and greater consideration of disease
burden was recommended. Recently the NIH disease
funding levels was compared to burden of disease [16].
The authors concluded that in 2006 the levels of dis-
ease-specific funding correlated only modestly with US
burden of disease (which accounted for 33% of varia-
tion) and correlation did not improve compared to 1996
levels. Similar results were obtained for estimates of
future US burden, as well as current and future global
disease burden.
The Brazilian MoH has some challenges ahead. To
work even closer and to prioritize research questions
relevant to the National Health Policy, focusing health
systems research in the areas of assistance, surveillance,
prevention and promotion. To induce investigations
aimed to practical applications in the fields of drug
development, new technologies and medical devices, as
well as in the traditional fields of health research.
Conclusions
As shown, Brazil implemented and fulfilled the NAPHR
financing health research priorities as defined. Further-
more, the funding allocation was in accordance with
economic and regional health characteristics and needs.
The affirmative policy to combat regional inequities in
health research was successful and should remain as a
permanent goal. A participatory process was in fact
established and this democratic management of health
research policy conferred legitimacy, permitting it to
become a part of the National Health Policy.
In conclusion, the joint efforts of the Department of
Science and Technology with the Ministry of Science
and Technology and its institutes (CNPq and FINEP), as
well as the State Foundations for Research Support
(FAPs) and other departments at the MoH, have
achieved and legitimated an unprecedented developmen-
tal spurt to support strategic health research. However,
nothing of this magnitude would have been achieved
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Page 8 of 9without a mature, responsive and committed local scien-
tific community.
We believe our experience is valuable and applicable
to other countries. Of course, different settings and local
political circumstances will determine the best course of
action to follow.
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